tert-butyl 1-(5-bromopyridin-2-yl)pyrrolidin-3-ylcarbamate | 1088410-93-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: tert-butyl 1-(5-bromopyridin-2-yl)pyrrolidin-3-ylcarbamate
• 英文别名: tert-Butyl (1-(5-bromopyridin-2-yl)pyrrolidin-3-yl)carbamate；tert-butyl N-[1-(5-bromopyridin-2-yl)pyrrolidin-3-yl]carbamate
• CAS: 1088410-93-8
• 化学式: C₁₄H₂₀BrN₃O₂
• 分子量: 342.236
• InChiKey: ZBJHINVCNZFKMV-UHFFFAOYSA-N

物化性质

• 沸点：
  458.8±45.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090

反应信息

• 作为产物：
  描述：

  2-氟-5-溴吡啶 、 3-(Boc-氨基)吡咯烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 6.0h， 以36%的产率得到tert-butyl 1-(5-bromopyridin-2-yl)pyrrolidin-3-ylcarbamate
  参考文献：
  名称：

  EP2166015

  摘要：

  公开号：

文献信息

• NOVEL MCH RECEPTOR ANTAGONISTS
  申请人：Amegadzie Albert Kudzovi

  公开号：US20100016350A1

  公开（公告）日：2010-01-21

  The present invention relates to a melanin concentrating hormone antagonist compound of formula (I): wherein R 1 , R a , R b , R 2 , L 1 , R 3 , R 4 and R 5 are as defined, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture of diasteromers thereof useful in the treatment, obesity and related diseases.

  本发明涉及一种公式(I)的黑色素浓集激素拮抗剂化合物：其中R1、Ra、Rb、R2、L1、R3、R4和R5如定义，或其药学上可接受的盐、对映体、非对映体或其混合物，适用于治疗肥胖症及相关疾病。
• LINCOSAMIDE DERIVATIVES AND ANTIMICROBIAL AGENTS COMPRISING THE SAME AS ACTIVE INGREDIENT
  申请人：Umemura Eijirou

  公开号：US20100184746A1

  公开（公告）日：2010-07-22

  An objective of the present invention is to provide compounds of formula (I) or their pharmacologically acceptable salts or solvates wherein A represents aryl while R 1 represents a five- or six-membered monocyclic heterocyclic group, or A represents a four- to six-membered monocyclic heterocyclic group while R 1 represents aryl or a five- or six-membered monocyclic heterocyclic group; R 2 represents a hydrogen atom or C 1-6 alkyl; R 3 represents C 1-6 alkyl or C 3-6 cycloalkyl-C 1-4 alkyl; R 4 , R 5 , and R 6 represent a hydrogen atom; R 7 represents C 1-6 alkyl; and m is 1 to 3. The compounds are novel lincosamide derivatives that have a potent activity against resistant Streptococcus pneumoniae . Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.

  本发明的目标是提供式（I）的化合物或其药理学上可接受的盐或溶剂，其中A代表芳基，而R1代表五元或六元单环杂环基，或A代表四至六元单环杂环基，而R1代表芳基或五元或六元单环杂环基；R2代表氢原子或C1-6烷基；R3代表C1-6烷基或C3-6环烷基-C1-4烷基；R4、R5和R6代表氢原子；R7代表C1-6烷基；m为1至3。这些化合物是新型的林可霉素衍生物，对耐药性肺炎链球菌具有强效活性。此外，这些化合物可用作抗微生物剂，对预防或治疗细菌感染性疾病有用。
• Lincosamide derivatives and antimicrobial agents comprising the same as active ingredient
  申请人：Meiji Seika Kaisha, Ltd.

  公开号：US07867980B2

  公开（公告）日：2011-01-11

  An objective of the present invention is to provide compounds of formula (I) or their pharmacologically acceptable salts or solvates wherein A represents aryl while R1 represents a five- or six-membered monocyclic heterocyclic group, or A represents a four- to six-membered monocyclic heterocyclic group while R1 represents aryl or a five- or six-membered monocyclic heterocyclic group; R2 represents a hydrogen atom or C1-6 alkyl; R3 represents C1-6 alkyl or C3-6 cycloalkyl-C1-4 alkyl; R4, R5, and R6 represent a hydrogen atom; R7 represents C1-6 alkyl; and m is 1 to 3. The compounds are novel lincosamide derivatives that have a potent activity against resistant Streptococcus pneumoniae. Further, the compounds are usable as antimicrobial agents and are useful for preventing or treating bacterial infectious diseases.

  本发明的目标是提供式（I）的化合物或其药学上可接受的盐或溶剂，其中A代表芳基，而R1代表五元或六元单环杂环基，或A代表四元至六元单环杂环基，而R1代表芳基或五元或六元单环杂环基；R2代表氢原子或C1-6烷基；R3代表C1-6烷基或C3-6环烷基-C1-4烷基；R4、R5和R6代表氢原子；R7代表C1-6烷基；m为1至3。这些化合物是新型的林可霉素衍生物，对耐药性肺炎链球菌有强效活性。此外，这些化合物可用作抗微生物剂，并可用于预防或治疗细菌感染性疾病。
• Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
  申请人：Rami Harshad Kantilal

  公开号：US20090163506A1

  公开（公告）日：2009-06-25

  Certain compounds of formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R 1 , R 2 , P, P′, n, p, q, r and s are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

  某些式(I)的化合物，或其药学上可接受的盐，或其溶剂化物，其中R1、R2、P、P′、n、p、q、r和s的定义如规范所述，制备这种化合物的过程，包括这种化合物的药物组成物，以及这种化合物和组成物在医学上的使用。
• Urea compounds active as vanilloid receptor antagonist for the treatment of pain
  申请人：Glaxo Group Limited

  公开号：EP2036902A2

  公开（公告）日：2009-03-18

  Certain compounds of formula (I), or a pharmaceutically acceptable salt thereof, or a solvate thereof, wherein R1, R2, P, P', n, p, q, r and s are as defined in the specification, a process for preparing such compounds, a pharmaceutical composition comprising such compounds and the use of such compounds and composition in medicine.

  某些式(I)化合物、 或其药学上可接受的盐，或其溶液，其中 R1、R2、P、P'、n、p、q、r 和 s 如说明书中所定义；制备此类化合物的工艺；包含此类化合物的药物组合物；以及此类化合物和组合物在医药中的用途。